English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significance Recombinant immunotoxins are anticancer agents consisting of Fv of an antibody that targets a cancer cell and a protein toxin that kills the cell. Despite its short half-life in the circulation, Moxetumomab pasudotox is a recombinant immunotoxin that has produced many complete regressions in patients with leukemia, because the leukemia cells are readily accessible to the agent. Immunotoxins targeting solid tumors are less active, because it takes many hours to enter bulky tumors and by then the blood levels have fallen to ineffective levels. To overcome this deficiency, we have designed and produced a generation of immunotoxins containing albumin-binding domains that dramatically increase their half-life in the circulation and antitumor activity in mice.

Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity